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Human papillomavirus is the principal risk factor associated with cervical cancer, the most common malignancy among
women in Colombia. We conducted a survey, aiming to report type speciﬁc prevalence and determinants of human
papillomavirus infection in women with normal cytology. A total of 1859 women from Bogota, Colombia were
interviewed and tested for human papillomavirus using a general primer GP5+/GP6+ mediated PCR–EIA. The overall
HPV DNA prevalence was 14.8%; 9% of the women were infected by high risk types, 3.1% by low risk types, 2.3% by
both high risk/low risk types and 0.4% by uncharacterized types (human papillomavirus X). Thirty-two different human
papillomavirus types were detected, being human papillomavirus 16, 58, 56, 81(CP8304) and 18 the most common types.
The human papillomavirus prevalence was 26.1% among women younger than 20 years, 2.3% in women aged 45–54
years, and 13.2% in women aged 55 years or more. For low risk types the highest peak of prevalence was observed in
women aged 55 years or more. Compared to women aged 35–44 years, women aged less than 20 years had a 10-fold
increased risk of having multiple infections. Besides age, there was a positive association between the risk of human
papillomavirus infection and number of regular sexual partners and oral contraceptive use. In women aged below 25
years, high educational level and having had casual sexual partners predicted infection risk. In conclusion, there was a
broad diversity of human papillomavirus infections with high risk types being the most common types detected. In this
population multiplicity of sexual partners and, among young women, high educational level and casual sexual partners
seem to determine risk.
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Cervical cancer is the most common cancer among women in
developing countries, and the sixth most common cancer in
women in developed countries (Parkin et al, 1999). In Colombia,
where the annual standardised incidence rate of cancer of the
cervix is high (23 per 100000), it is also the principal cause of
cancer mortality among women (Globocan, 1998).
Infection with certain types of human papillomavirus (HPV) is
the main cause of cervical cancer and its precursor lesions (Van
den Brule et al, 1991; Mun ˜oz et al, 1992; Chichareon et al, 1998;
Ngelangel et al, 1998; Rolon et al, 2000). HPV infection is now
considered as virtually necessary but not sufﬁcient to cause this
malignancy (Walboomers et al, 1999). Other host factors such as
genetic alterations, endogenous female hormones and immune
status or environmental factors (e.g. smoking and use of exogenous
hormones) are also likely to be involved in cervical carcinogenesis
(Bosch et al, 1992; Ngelangel et al, 1998; Gostout et al, 1998;
Palefsky et al, 1999).
On the basis of their main association with benign or (pre-)
malignant lesions, HPVs can be subdivided into low risk (LR)
and high-risk (HR) oncogenic types. Women with normal cervical
cytology who are infected with HR HPV have an approximately
100-fold increased risk of developing CIN III compared to unin-
fected women (Rozendaal et al, 1996). Therefore, it has been
suggested that HR HPV detection might be used as a tool to iden-
tify women at high risk of cervical cancer, in addition to – or as
an alternative to – Pap smears (Rozendaal et al, 1996, 2000; Meijer
et al, 1998).
The marked geographic differences in incidence of cervical
cancer are not only the result of differences in screening patterns,
but also of differences in exposure to risk factors. For example, the
very low incidence rates (2–4 per 100000) reported from some
areas in China and Spain (Parkin et al, 1997) where population-
based screening programs do not exist, are probably the result of
low exposure to HPV resulting from the conservative sexual beha-
viour prevalent in the previous decades.
To investigate geographic differences in the prevalence of type-
speciﬁc HPV infection and of other risk factors for cervical cancer,
the International Agency for Research on Cancer is co-ordinating a
series of surveys of prevalence of HPV infection and CIN lesions in
countries with high and low incidence of cervical cancer, this study
being one of them.
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Table 1 Characteristics of the study population of HPV-DNA detection among women with normal cytology
in Bogota, Colombia
Proportion of women positive for HPV-
DNA
No Overall % % any HPV-DNA
b %H R
a %L R
a
Total 1845 100 14.9 11.4 3.2
Age (years)
c
520 230 12.4 26.1 20.4 5.2
20–24 220 11.8 22.7 18.2 4.1
25–29 337 18.1 12.7 10.4 1.8
30–34 404 21.7 16.6 11.9 4.2
35–39 284 15.3 8.1 6.0 2.1
40–44 192 10.3 8.1 7.8 0.5
45–54 86 4.6 2.3 2.3 0.0
555 106 5.7 13.2 5.7 7.6
Education
Low 659 35.7 11.7 8.3 3.2
Intermediate 740 40.1 15.5 12.3 2.9
High 445 24.1 18.9 14.4 3.6
Missing 1 0.1 0.0 0.0 0.0
Age at 1st sexual intercourse
520 628 34.0 11.9 9.1 2.5
17–19 585 31.7 14.7 10.9 3.4
416 632 34.3 18.2 14.1 3.6
Age at 1st regular sexual intercourse
520 759 41.1 11.7 8.9 2.5
17–19 556 30.1 15.6 11.7 3.6
416 478 26.0 18.6 14.4 3.5
Missing 52 2.8 21.1 15.3 5.7
Number of regular sexual partners
1 1370 74.3 14.0 10.9 2.7
2 299 16.2 17.4 12.7 3.7
3 59 3.2 22.0 15.2 6.8
Missing 117 6.3 16.2 11.1 5.1
Casual sexual partners
No 1307 70.8 13.8 10.5 2.8
Yes 445 24.1 18.2 13.9 4.0
Missing 93 5.0 15.0 10.7 4.3
Parity
0–1 644 34.9 29.2 22.0 6.2
2–3 845 45.8 14.4 11.3 2.5
54 356 19.3 11.4 8.3 3.2
Age at ﬁrst birth
521 843 45.7 10.4 7.8 2.2
18–20 493 26.7 16.2 12.4 3.4
417 293 15.9 15.7 12.6 3.1
Missing
d 216 11.7 28.7 21.3 6.5
Oral contraceptives
Never 957 51.9 13.8 10.3 3.0
Ever 845 46.3 16.3 12.4 3.5
Former user 721 39.1 15.4 12.0 2.9
Current user 133 7.2 21.0 14.3 6.7
Missing 34 1.8 14.7 14.7 0.0
IUD (Intrauterine Device)
Never 779 42.2 15.8 12.2 3.1
Ever 1032 56.0 14.2 10.7 3.3
Former user 524 28.4 14.1 10.5 3.6
Current user 508 27.6 14.4 10.8 2.9
Missing 34 1.8 17.6 14.7 2.9
Condom
Never 1203 65.2 13.7 10.2 3.1
Ever 618 33.5 17.5 13.7 3.4
Missing 24 1.3 12.5 8.3 4.1
Continued
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(3), 324–333The prevalence of HPV, as detected by HPV DNA, characteris-
tically peaks after initiation of sexual activity and decreases with
age. A second peak in peri-menopausal women has been recently
described in some populations (Cuzick et al, 1999; Herrero et al,
2000; Lazcano et al, 2001). It is currently unknown whether
different age-speciﬁc curves of HPV prevalence are attributable
to an effect of age per se or to differences in risk between birth
cohorts.
A prospective cohort study in Bogota, Colombia, was initiated in
the early 1990s by the Colombian National Institute of Cancer and
the International Agency for Research on Cancer (IARC). The aim
of this study was to investigate the natural history of HPV infection
and CIN lesions among low-income Colombian women. We report
here the results of a cross-sectional analysis of the cohort at enrol-
ment, with focus on determinants of HPV infection among women
with normal cervical cytology.
MATERIALS AND METHODS
Study population
Between November 1993 and November 1995 the Colombian
National Cervical Cancer Control Program conducted a census
in four health districts in Bogota, which had no previously
implemented population-based cervical screening program. The
ﬁrst 2000 women aged 18–85 years identiﬁed in the census
were invited to participate in the study. Additionally, 200
adolescents aged 13–17 years were invited to participate. They
were identiﬁed consecutively from an adolescent clinic giving
contraceptive counselling in the study area. At recruitment, all
women were interviewed face-to-face by specially trained inter-
viewers. They answered to a structured questionnaire on
socio-demographic characteristics, lifelong sexual behaviour,
reproductive and menstrual history, and smoking and dietary
habits. After interview all women underwent a pelvic examina-
tion.
From the 2200 invited women, 53 refused to participate, eight
were considered ineligible (mental illness, hysterectomy, history
of cervical cancer) and 29 did not provide cell specimens for
HPV DNA detection, so that 2110 women had cell specimens to
be analysed. Of them 150 had abnormal cytology (according to
the Bethesda system classiﬁcation) and 101 of the women with
normal cytology were beta-globin PCR negative (which is consid-
ered an indicator of poor DNA quality). After these exclusions,
1859 women remained in the analysis presented here. In the multi-
variate analysis (see below) we further excluded 14 women who did
not answer the questionnaire completely, resulting in 1845 women
with normal cytology and risk factors analysis. Informed consent
was obtained from all participants included in the study. The local
ethical committee and the ethical committee at IARC approved the
study protocol.
Biological specimens
During the gynaecological examination, cervical scrapes were
collected from each woman using two Ayre spatulas and two endo-
cervical brushes. The ﬁrst spatula and brush were used for a
routine Pap smear, which was classiﬁed according to the Bethesda
system terminology. The second spatula and brush and the remain-
ing cells of the ﬁrst spatula and brush, were placed in a tube
containing 5 ml of phosphate-buffered saline (PBS 16)+0.05%
thiomersal. Cells were detached from the spatula and endocervical
brush through vortex, and subsequently centrifuged at 3000 g for
10 min. The cell pellet was resuspended in 1 ml buffer Tris-HCl
10 mM pH 8.3 and stored at 7708C until their use. For analysis,
100 ml aliquots were boiled for 10 min at 1008C, cooled on ice
and centrifuged for 1 min at 30006g. 10 ml of these pre-treated
crude cell suspensions were used for PCR analysis (Van den Brule
et al, 1990; De Roda Husman et al, 1994). To assess the quality of
the target DNA, all pellets were pre-screened using a 209 base pair
amplifying b-globin PCR using the primer combination BPCO3
and BPCO5 as described by De Roda Husman et al (1995b).
HPV detection by PCR
HPV-DNA detection was performed by a standard GP5+/GP6+
PCR based assay, as described by De Roda Husman et al
(1995a). Brieﬂy, the GP–PCR reaction was carried out using
50 ml of PCR solution containing 10 mM Tris HCL pH 8.3,
50 mM KCl, 200 mM of each deoxynucleotide, 3.5 mM of MgCl2,
1 U of DNA polymerase (AmpliTaq; Perkin-Elmer, USA) and
25 pmol of each of the GP5+ and biotinylated GP6+ primers
(Eurogentec, Belgium): 40 cycles of ampliﬁcation were carried
out using a Perkin-Elmer 9600,USA thermocycler. Each cycle
included a denaturation step at 958C for 1 min, one annealing step
at 408C for 1 min, and a chain elongation step at 728C for 1.5 min.
The ﬁrst step was preceded by a denaturation step of 4 min and
the last step was followed by an elongation step of 10 min.
Three dilutions of the cell line SiHa containing 1–10 copies of
HPV16 (100 pg, 1 ng and 10 ng) were used as positive control. As
negative PCR controls, distilled water and processing blanks were
used every 10 samples. HPV positivity was assessed by Southern
blot hybridization of GP5+/GP6+ PCR products with a cocktail
probe of speciﬁc [a-
32P]dCTP labelled DNA fragments from cloned
DNA of HPV6, 11, 16, 18, 31 and 33 under low stringent condi-
tions (Van den Brule et al, 1990; De Roda Husman et al, 1995a,b).
Type speciﬁc HPV detection
HPV positive samples were ﬁrst subjected to HPV group-speciﬁc
analysis using cocktail probes for HR and LR HPVs (Jacobs et al,
1997, 2000). The HR HPV cocktail probe consisted of oligoprobes
for HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68
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Table 1 (Continued)
Proportion of women positive for HPV-
DNA
No Overall % % any HPV-DNA
b %H R
a %L R
a
Smoking
Never 1343 72.8 14.7 11.3 3.0
Ever 502 27.2 15.7 11.6 3.6
Former smoker 205 11.1 14.1 9.7 3.9
Current smoker 297 16.1 16.8 12.8 3.4
aHigh-risk (HR) types: 16, 18, 26, 31, 33, 34, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68 ISO39. Low-risk (LR) types: 6, 11, 40, 42,
43, 44, 82 (MM4), 83 (MM7), 84 (MM8), 71 (CP8061), CP6108, 81 (CP8304), 54, 55, 57, 61, 70, 72, 73.
bProportion of women
infected with any HPV types, HR and LR types, respectively, in each category of age, education, etc. When women were
infected by both HR and LR simultaneously they were counted in the HR group only.
cInformation on age was available for
1859 individuals.
dInclude nulliparous women.
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British Journal of Cancer (2002) 87(3), 324–333 ã 2002 Cancer Research UKand the LR HPV consisted of oligoprobes for HPV 6, 11, 40, 42,
43, 44, HPV 82 (MM4), HPV83 (MM7), HPV84 (MM8), Iso39,
HPV71 (CP8061), CP6108, HPV 81 (CP8304), HPV 26, 34, 53,
54, 55, 57, 61, 70, 72, 73. However HPV types with unknown
oncogenic potential – namely 26, 53, 73, 34 and Iso 39 – were
considered in the results as HR types, based on both the align-
ment analysis of the E6 gene (modiﬁed from Myers et al, 1996)
and the risk estimates obtained for the various HPV types within
a multi-center case–control study of cervical cancer conducted by
the IARC (Mun ˜oz et al, 1992, Mun ˜oz, 2000; Bosch et al, 1995;
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Figure 1 Prevalence of high and low risk of human papillomavirus among women with normal cytology from Bogota, Colombia
Table 2 Prevalence of type-speciﬁc HPV single infection by age-group, in women with normal cytology
Age 525 years Age 25–34 years Age 535 years All ages
a
(n=450) (n=741) (n=668) (n=1859)
HPV type No No No No %
6 010 1 0 . 4
11 1 2 1 4 1.4
16 12 20 13 45 16.3
18 4 4 0 8 2.9
31 2 2 1 5 1.9
33 1 2 1 4 1.4
34 0 1 0 1 0.4
39 2 3 1 6 2.2
40 3 1 1 5 1.9
42 2 2 3 7 2.5
45 2 1 0 3 1.1
51 2 3 3 8 2.9
52 1 3 2 6 2.2
53 0 2 0 2 0.7
54 2 0 2 4 1.4
56 5 3 2 10 3.6
58 9 5 3 17 6.2
59 0 1 0 1 0.4
61 0 1 0 1 0.4
66 2 2 0 4 1.4
68 0 2 0 2 0.7
70 2 1 1 4 1.4
72 1 1 0 2 0.7
81 (CP8304) 3 5 2 10 3.6
Iso 39 0 1 0 1 0.4
82 (MM4) 0 1 0 1 0.4
83 (MM7) 2 0 0 2 0.7
84 (MM8) 0 2 2 4 1.4
HR (cocktail) 3 3 3 9 3.3
LR (cocktail) 4 5 1 10 3.6
HPV X 2 4 1 7 2.5
Total 67 84 43 194 70.3
a % relative to 276 HPV-positive women.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(3), 324–333Chaouki et al, 1998; Chichareon et al, 1998; Ngelangel et al, 1998;
Rolon et al, 2000).
Brieﬂy, in the enzyme immune assay (EIA), 5 ml of the biotiny-
lated PCR products were captured in streptavidine-coated
microtitle plates (Roche, Mannheim, Germany). Subsequently,
the wells were washed three times with 16SSC; the captured
DNA was denatured by alkaline treatment with 0.1 M NaOH
and hybridised to digoxigenin-labelled type-speciﬁc oligoprobes.
After several washings the hybrids were detected using anti-digox-
igenin (Fab fragments) labelled with alkaline phosphatase (Roche,
Mannheim, Germany) and paranitrophenyl phosphate (Sigma,
USA) was used as substrate. The optical density (OD) was
measured at 405 nm using a Labsystem Multiscan reader. In
our assay a cut-off point was deﬁned using three times mean
OD of the negative controls.
The HPV positive samples were analysed successively in other
speciﬁc EIA probe sub-cocktails and ﬁnally speciﬁc oligoprobes
were used to identify each individual HPV type. Samples which
were positive by Southern blot analyses and negative by HR and
LR EIA, were considered as positive for HPV of undetermined type
(HPV X).
Data analysis
We computed odds ratios (ORs) and 95% conﬁdence intervals (CI)
using unconditional logistic regression models, considering HPV
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Table 3 Risk factors for HPV-DNA detection among women with normal cytology
Positive for HPV-DNA Positive for HPV-DNA Positive for HPV-DNA
detection HR types
a LR types
b
No OR
a No OR
a No OR
a
Age (years)
520 60 4.2 (2.1–8.3) 47 3.7 (1.8–7.9) 12 9.6 (2.2–42.0)
20–24 50 3.7 (2.2–6.4) 40 3.5 (2.0–6.4) 9 6.0 (1.8–19.6)
25–29 43 1.6 (1–2.7) 35 1.7 (1.0–2.8) 6 3.8 (1.4–4.8)
30–34 67 2.1 (1.4–3.3) 48 1.8 (1.1–3.0) 17 3.8 (1.4–10.0)
35–44 40 1 (reference) 32 1 (reference) 7 1 (reference)
545 16 1.2 (0.6–2.3) 8 0.8 (0.3–1.8) 8 3.2 (1.0–10.3)
Education
Low 77 1 55 1 21 1
Intermediate 115 1 (0.7–1.5) 91 1.0 (0.7–1.6) 22 0.9 (0.4–2.0)
High 84 1.4 (0.9–2.1) 64 1.4 (0.9–2.3) 16 1.3 (0.5–3.0)
No of regular sexual partners
1 192 1 150 1 38 1
2 52 1.4 (1.0–2.0) 38 1.3 (0.9–2) 11 1.5 (0.7–3.1)
3 13 2.1 (1.1–4.2) 9 2 (0.9–4.5) 4 3.0 (0.9–9.7)
Casual sexual partners
No 181 1 138 1 37 1
Yes 81 1.1 (0.8–1.5) 62 1.1 (0.8–1.6) 18 1.3 (0.7–2.5)
Parity
06 1 1 4 6 1 1 3 1
1–2 136 0.7 (0.4–1.1) 107 0.7 (0.4–1.1) 24 0.7 (0.3–1.8)
53 79 0.7 (0.4–1.3) 57 0.7 (0.4–1.4) 22 1.0 (0.3–3.0)
Age at ﬁrst sexual intercourse
520 75 1 57 1 16 1
17–19 86 1.0 (0.7–1.4) 64 1.0 (0.7–1.5) 20 1.0 (0.5–2.1)
416 115 1.0 (0.6–1.5) 89 1.0 (0.6–1.6) 23 0.7 (0.3–1.8)
Oral contraceptives
Never 132 1 99 1 29 1
Ever 139 1.4 (1.1–1.9) 106 1.4 (1.0–1.9) 30 1.6 (0.9–2.9)
Former user 111 1.4 (1–1.9) 87 1.4 (1.0–2.0) 21 1.3 (0.7–2.5)
Current user 28 1.5 (0.9–2.4) 19 1.2 (0.7–2.2) 9 3.1 (1.3–7.2)
IUD
Never 123 1 95 1 24 1
Ever 147 1.1 (0.8–1.5) 110 1.0 (0.7–1.4) 34 1.6 (0.8–3.0)
Former user 74 1.4 (0.9–1.8) 55 1.2 (0.8–1.7) 19 1.8 (0.9–3.8)
Current user 73 1.5 (0.7–1.4) 55 0.9 (0.6–1.3) 15 1.3 (0.6–2.9)
Condom
Never 165 1 123 1 37 1
Ever 108 1.1 (0.7–1.3) 85 1.0 (0.7–1.4) 21 0.8 (0.4–1.4)
Smoking
Never 197 1 152 1 41 1
Ever 79 1.1 (0.8–1.5) 58 1.1 (0.8–1.5) 18 1.2 (0.6–2.3)
Former smokers 29 1.0 (06–1.6) 20 0.9 (0.5–1.6) 8 1.2 (0.5–3.0)
Current smoker 50 1.2 (0.8–1.7) 38 1.2 (0.8–1.8) 10 1.2 (0.5–2.6)
OR
a=odds ratio adjusted for age, education, number of regular partners, parity, age at ﬁrst sexual intercourse, oral contraceptives, condom use and smoking habit.
aHigh-risk
(HR) types: 16, 18, 26, 31, 33, 34, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68 ISO39.
bLow-risk (LR) types: 6, 11, 40, 42, 43, 44, 82 (MM4), 83 (MM7), 84 (MM8), 71 (CP8061),
CP6108, 81 (CP8304), 54, 55, 57, 61, 70, 72, 73.
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British Journal of Cancer (2002) 87(3), 324–333 ã 2002 Cancer Research UKinfections as dependent variables and several known or hypothe-
sised risk factors for cervical cancer as independent variables
(STATA; Stata Press, College Station, TX, USA). We performed
both age adjusted (grouped as 520, 20–24, 25–29, 30–34, 35–
39, 40–44, 45–54, 55 or more years) and multivariate analyses.
The following variables were included in the models: age (as cate-
gorised above), educational level (low, intermediate and high),
number of regular (1, 2, 3 or more) sexual partners, parity (0,
1–2, 3 or more children), age at ﬁrst sexual intercourse (less 17,
17–19, 20 or more years), use of oral contraceptives (ever or never
use), condoms (ever or never use), and smoking habits. The differ-
ent age-adjusted and multivariate models did not differ materially
from each other. Therefore we present in this report only results of
the fully adjusted multivariate models.
RESULTS
Characteristics of the study population
The characteristics of the study population are summarised in Table
1. Most of the participating women were aged 25–34 years
(median age 32), had low (36%) or intermediate (40%) educational
level, had their ﬁrst sexual intercourse or ﬁrst regular sexual partner
before the age of 20 (median 18 and 19 years, respectively),
reported a single regular lifelong sexual partner (74%), and had
at least two full term pregnancies (median=2). Intrauterine device
(IUD) was the most common contraceptive method ever used
(56%), followed by oral contraceptives (46.3%) and condoms
(33.5%). Only one third of the women had ever smoked regularly.
HPV-DNA prevalence
The overall HPV-DNA prevalence rate was 14.9% (Table 1), and 32
different HPV types were detected. Of the HPV-DNA positive
women, 9% were infected with HR types only, 3.2% with LR types
only, and 0.4% with HPV X. 2.3% of women were infected with
both HR/LR types, which were grouped together with HR types
in all analysis. Thus the total HR type prevalence was 11.4% (Table
1). HPV-DNA age-speciﬁc prevalence was highest among women
below age 20 (26%), and lowest among women aged 45–54 years
(2.3%). Women aged 55 or more years had a prevalence rate of
13.2% (Table 1).
HR HPV types were at least three times more prevalent than LR
types in all age groups, except among women aged 55 or more years
(Table 1). Similarly to the overall HPV prevalence, the HR age-speci-
ﬁc prevalence rate curve presented a U-shape (Figure 1), the highest
prevalence being among women aged less than 20 years (20.4%), the
lowest among women aged 45–54 years (2.3%), and an intermediate
among women aged 55 years or more (5.7%). For LR types, the age
speciﬁc pattern was rather different: while no women aged 45–54
years were positive, those aged 55 years or more had the highest
prevalence rate (7.6%) of all age groups. Thus, among older women,
LR types were more common than HR types (Figure 1).
Single infections (infections with only one HPV type) were
detected in 194 women (10.4% of the entire study population;
70.3% of the HPV positive women). Among these women, the
most common HPV HR types were 16 (16.3% of the women with
single infections), 58 (6.2%), 56 (3.6%) and 18 and 51 (2.9%). The
most frequent HPV LR types were HPV 81 (CP8304) (3.6%), 42
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Table 4 Risk factors for HPV-DNA detection in women with normal cytology by age groups
Age
525 years 25–34 years 535 years
n=450 n=741 n=668
HPV+ (%) OR
a HPV+ (%) OR
a HPV+ (%) OR
a
Education
Low 15.5 1 14.8 1 9.1 1
Intermediate 23.6 1.6 13.7 1.0 6.0 0.7
(0.8–3.5) (0.6–1.7) (0.3–1.4)
High 35.0 2.6 16.5 1.0 10.1 1.1
(1.1–6.1) (0.5–2.0) (0.5–2.6)
Number of regular partners
1 22.6 1 12.4 1 9.4 1
52 38.8 2.1 23.0 1.9 7.0 0.6
(1.1–4.1) (1.2–3.0) (0.3–1.3)
Casual partners
No 21.9 1 13.7 1 9.1 1
5Yes 33.3 1.7 17.2 1.1 7.2 0.7
(1.0–2.9) (0.6–1.7) (0.3–1.6)
Parity
0 31.5 1 30.2 1 10.0 1
1–2 21.1 0.9 13.4 0.5 8.0 0.6
(0.5–1.5) (0.2–1.2) (0.1–3.0)
3+ 22.2 1.2 15.0 0.5 8.7 0.6
(0.4–3.7) (0.2–1.2) (0.1–2.9)
Oral contraceptives
Never 23.0 1 11.8 1 7.9 1
Ever 27.0 1.4 18.0 1.5 9.4 1.4
(0.9–2.4) (0.9–2.3) (0.5–2.1)
Former user 23.0 1.2 19.0 1.6 9.3 1.3
(0.7–2.1) (1.0–2.5) (0.7–2.5)
Current user 34.6 2.0 12.7 0.9 11.1 1.7
(0.6–1.5) (0.4–2.2) (03–8.2)
OR
a=odds ratio adjusted for age, education, number of regular partners, parity, age at ﬁrst sexual intercourse, oral contraceptives, condom use
and smoking habit.
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infection decreased with age, the same HPV types being the
commonest ones in all age groups (Table 2).
Multiple infections (infections with two or more HPV types)
were detected in 82 women (4.4% of the entire study population;
29.7% of the HPV positives). Women aged less than 25 years had
an almost ﬁve times higher prevalence rates of multiple infections
(9.6%) than women aged 35 years or more (1.9%). Most of the
multiple infections were caused by HR/LR types (53.7%) or HR/
HR types (42.7%) and less (3.6%) by LR/LR types. Among women
with multiple infections, HR types were present in 97.6% of those
women aged less than 25 years, 100% among those aged 25–34
years, and 85.7% among those aged 35–54 years, and 83.3% among
those aged 55 or more years. HPV 35, 43, 44 and CP6108 were
detected only in multiple infections (data not shown).
Risk factors for HPV infections
Besides age, number of regular sexual partners and OC use, no
other risk factors were clearly associated with overall risk for
HPV infections in our study population (Tables 1 and 3). For
HR HPV infections, there was a trend of a decreased risk among
women with parities (OR 0.7), and of an increased risk among
users of oral contraceptives (OR 1.4, 95% CI 1.0–1.9). For LR
types, current use of oral contraceptives increased the infection risk
signiﬁcantly (OR 3.1, 95% CI 1.3–7.2) and use of IUD also tended
to increase the risk of infection (OR 1.6, 95% CI 0.8–3.0 – Table
3). Although there was no statistically signiﬁcant interaction
between the effects of age and other potential risk factors for
HPV infections, some interesting age-speciﬁc patterns emerged in
the analysis, of which some are presented in Table 4.
In women below the age of 25 years, high educational level (OR
2.6, 95% CI 1.1–6.1), and more than a single regular (OR 2.1,
95% CI 1.1–4.1) or casual (OR 1.7, 95% CI 1.0–2.9) sexual partner
predicted infection risk (Table 4). There was also a suggestion of an
increased risk with current use of oral contraceptives (OR 2.0, 95%
CI 0.6–1.5 – Table 4). The addition of women attending an adoles-
cent clinic (age 13–17 years) did not generate a bias in the study
results, since no statistically signiﬁcant differences were found when
they were excluded from the analysis. The association with number
of partners persisted with a slightly lower odds ratio (OR 1.7, 95%
CI 0.7–4.2). On the other hand, the association with education
was stronger (OR 7.4, 95% CI 1.9–29.0 for high level of education).
In the age group 25–34 years, having had more than one regu-
lar sexual partner increased HPV infection risk (OR 1.9, 95% CI
1.3–3.0 – Table 4). There was no clear association between the
existence of casual sexual partners, age at ﬁrst sexual intercourse
or ﬁrst birth, use of IUDs or condoms and risk. Former use of oral
contraceptives increased the infection risk slightly (OR 1.6, 95% CI
1.0–2.5) and parity slightly decreases the risk (OR 0.5, 95% CI
0.2–1.2). No clear pattern of association was observed among
women aged 35 or more years. The study had insufﬁcient women
of the age of 55 years or more to allow further subgroup analysis
with meaningful statistical power.
Young age and high level of attained education were better
predictors of multiple infections than of single ones (Table 5).
For multiple infections, there was a trend for a protective effect
of parity (for three or more children compared to nulliparous,
OR 0.5, 95% CI 0.2–1.3) and use of condoms (OR 0.5, 95% CI
0.3–0.9) (Table 5). In most instances, however, examined charac-
teristics shared similar associations with single and multiple
infections.
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Table 5 Risk-factors for HPV-DNA multiple detection in women from Bogota, Colombia
HPV single detection HPV multiple detection
Number OR
a Number OR
a
Age (years)
520 33 2.8 (1.3–6.3) 27 10.8 (3.0–38.4)
20–24 34 3.1 (1.7–5.7) 16 6.8 (2.3–20.2)
25–29 28 1.2 (0.7–2.2) 15 3.7 (1.3–10.3)
30–34 56 2.1 (1.3–3.4) 11 2.1 (0.7–6.0)
35–44 33 1 (reference) 7 1 (reference)
545 10 0.8 (0.4–1.8) 6 3.2 (1.0–10.7)
Education
Low 57 1 20 1
Intermediate 81 1.0 (0.7–1.5) 34 1.1 (0.5–2.2)
High 56 1.2 (0.7–1.9) 28 2.1 (1.0–4.5)
Number of regular sexual partners
1 138 1 54 1
2 36 1.3 (0.9–2.0) 16 1.7 (0.9–3.2)
3 9 2.0 (0.9–4.3) 4 2.9 (0.9–9.4)
Parity
0 35 1 26 1
1–2 97 0.7 (0.4–1.3) 39 0.6 (0.3–1.2)
53 62 0.9 (0.4–1.7) 17 0.5 (0.2–1.3)
Oral contraceptives
Never 92 1 40 1
Ever 101 1.3 (1.0–1.8) 38 1.6 (1.0–2.7)
Former user 83 1.3 (0.9–1.9) 28 1.6 (0.9–2.7)
Current user 18 1.3 (0.7–2.4) 10 1.8 (0.8–3.9)
Condom
Never 110 1 55 1
Ever 83 1.2 (0.9–1.7) 25 0.5 (0.3–0.9)
OR
a=odds ratio adjusted for age, education, number of regular partners, parity, age at ﬁrst sexual intercourse, oral contracep-
tives, condom use and smoking habit.
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To date, few studies evaluated age-speciﬁc HPV prevalence patterns
and determinants of HPV infection among women with normal
cytology in countries with high incidence of cervical cancer. We
report here the ﬁrst investigation of this type done in Colombia.
An overall HPV DNA prevalence of 14.9% was found, which is
similar to that reported in other high-risk populations in Mexico
(14.5%) (Lazcano et al, 2001) and Costa Rica (16%) (Herrero et
al, 2000). In addition, it is similar to the HPV-DNA prevalence
among control women (13%) in a concurrent case–control study
in Cali, Colombia (Mun ˜oz et al, 1996).
Several studies have suggested that the prevalence of HPV infec-
tion decreases with age, HPV being uncommon in cytological
normal women over age 35 years (Melkert et al, 1993; Morrison,
1994). However, a few recent large population-based surveys from
Costa Rica and Mexico also presented some increase in HPV infec-
tion among women in peri- and post-menopausal ages. While in
Costa Rica the peak was observed in women older than 55 years,
with a predominance of LR HPV types, in Mexico the second peak
started earlier, after 45 years of age, with predominance of HR
HPV types and with an increase in detection of LR HPV types
compared to younger ages.
In our study the HPV prevalence in the age group 45–54 years was
low, but there was an increased prevalence of HPV infection in
women aged 55 or more years, with a predominance of LR types
and multiple HPV infections, but still 5.7% were HR HPV positive.
If conﬁrmed, the risk of HPV infection – most notably LR types
– among post-menopausal women, it may be explained in different
ways: (1) reactivation of latent HPV infections by decreased immune
response. Some immunological studies show a decrease in circulating
mature T cells in older people as a result of a decrease in CD8+
lymphocytes, a decline in the frequency of CD4+ T cells producing
IL-2 and/or a decreased expression in IL-2 receptors (Lesourd and
Meaume, 1994; Gostout et al, 1998; Ginaldi et al, 1999). (2) Reactiva-
tion of latent HPV infections by hormonal changes related to the
gradual decline of ovarian function around menopause (Lazcano et
al, 2001). (3) A cohort effect (Herrero et al, 2000), where older
women were exposed to the virus early in life and belonged to genera-
tions more heavily exposed to HPV infections.
An alternative explanation for this second peak lies in the fact
that only women with normal cervical cytology were included in
this study. Persistent infections with HR HPV types will lead to
cervical intraepithelial lesions with subsequent treatment. It may
result in an under-representation of HR HPV types and the
proportion of them in the population will diminish at older age.
In contrast, LR HPV infections that rarely give rise to cervical
dysplasia will remain (Jacobs et al, 2000).
We identiﬁed 32 different HPV types in our study population.
This broad diversity of infections is consistent with previous
studies showing a greater HPV heterogeneity in mild cervical
dysplasias than in severe dysplasias (De Roda Husman et al,
1994; Liaw et al, 1999; Jacobs et al, 2000; Lazcano et al, 2001). It
has been estimated that at least 50% of sexually active adults have
ever had a genital HPV infection, most of these, however, being
transient and resolving spontaneously (Koutsky, 1997).
In our study HPV 16, 58, 56, 52, HPV 81 (CP8304), 51 and 18
were the most prevalent HPV types detected as single infections in
all age groups. Although HPV16 is the predominant type detected
in the majority of studies (Jacobs et al, 2000; Lazcano et al, 2001;
Rolon et al, 2000), remarkable differences were noted in our study
population with a high prevalence of other HPV types such as
HPV 56, 58 and the LR type HPV 81 (CP8304). This information
should be taken into account when developing HPV vaccines
tailored to this population.
In this study HPV 26, 53, 73, 34 and Iso 39 were analysed as
types with oncogenic potential according their presence in patients
with cervical cancer and the alignment analysis of the E6 gene
(modiﬁed from Myers et al, 1996). However the percentage of
these HPVs is very low and for absolute HR or LR classiﬁcation,
transformation studies in combination with follow up epidemiolo-
gical studies are necessary.
The presence of multiple infections (29.7%) was higher than
previously observed among control subjects in the IARC studies done
in Brazil (0%) (Eluf-Neto et al, 1994), the Philippines (14.3%)
(Ngelangel et al, 1998) Thailand (9.8%) (Chichareon et al, 1998),
Morocco (5.3%) (Chaouki et al, 1998) and Paraguay (16.7%) (Rolon
et al, 2000), lower than in a population-based study from Costa Rica
(39%) (Herrero et al, 2000) and similar to the results from a study
done in The Netherlands (28%) (Jacobs et al, 2000), where 3305 cyto-
logical normal cervical scrapes were analysed using the same
laboratory technique as in the present study. These differences in
prevalence of multiple infections could be due to differences in the
technique used (sensitivity, speciﬁcity and types identiﬁed), or real
differences in the prevalence of the HPV types searched for and iden-
tiﬁed in the populations studied. In addition, these populations
differed in age-composition: mean age 32 years in this study, whereas
in Thailand it was 49.7 years. Taking into account the age-dependent
prevalence of multiple infections, this fact may also explain the
discrepancy in results. In our study, 97% of the women with multiple
infections presented a HR HPV type. The long-term follow up of
these infections will help to clarify the role of HR multiple infections
in the development of cervical lesions.
Besides age, number of regular sexual partners and OC use
(specially in women below age 35 years) which were risk factors
for HPV positivity, other reproductive and sexual behaviour factors
considered by us were only weakly and inconsistently related to
HPV infection. It might be explained by the relatively high
frequency of HPV infections in the studied women and possibly
the predominance of ‘male role’ in the transmission of HPV infec-
tions to women (particularly over age 35 years). Unfortunately, no
information was available on the sexual behaviour of the partners
in our study population. Our results suggest an age-dependent
association between HPV infection and some risk factors. A possi-
ble explication of the highest prevalence of HPV infections among
young, highly educated women and with more than one regular or
casual sexual partner could reﬂect changes in lifestyle and sexual
behaviour in younger generations (possibly reduced inﬂuence of
religion and greater freedom).
We observed an increase of HPV infections and particularly of LR
types in women older than 55 years and we tried to analyse if these
women were different in terms of exposure to risk factors. Due to
the low number of women in this group we could not ﬁnd a clear
pattern of association. We found that use of oral contraceptives
may be a risk factor for both HR and LR HPV infections. Use of
exogenous hormones – as contraceptives or hormone replacement
– could inﬂuence HPV infections in different ways. Results from
laboratory work have indicated that the HPV genome contains a
hormone-recognition segment, which might show an interactive
effect of oral contraceptives and HPV (Monsonego et al, 1991). Addi-
tionally, steroid hormones do interfere with cellular gene function
involved in cell cycle regulation and apoptosis, and they also might
inhibit the immunologically mediated resolution of minor HPV-
induced cervical lesions (Von Knebel Doeboritz et al, 1997).
With respect to parity, in our study there was a trend of
decreased risk of HR and multiple HPV infections with increase
of number of births. Previous studies have presented conﬂicting
results: an increase in risk with number of births (Hildesheim et
al, 1993) or decrease or no association with parity at all (Lazcano
et al, 2001). There is still insufﬁcient data to give ﬁnal conclusions
about the effect of number of births on the risk of HPV infections.
In conclusion, our results showed a broad diversity of HPV
infections in women with normal cytology, with HR types being
at least three times more common than LR types. Whereas young
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
HPV in Colombia
M Molano et al
331
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(3), 324–333women were particularly at risk of HR and multiple HPV infec-
tions, post-menopausal women showed an increased frequency of
LR HPV types. In this population, high educational level and
multiplicity of sexual partners seem to determine risk among
young women. No other hypothesized risk factor was clearly asso-
ciated with the risk of HPV infection.
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